Jay Lichter

RQx Pharmaceuticals, Inc. operates as a biopharmaceutical company developing small molecule antibiotics. The firm develops small molecule antibiotics to combat serious life threatening infections, including those caused by multi drug-resistant Gram-negative bacteria. It is developing novel, first-in-class antibiotics that evade the current abundance of antibiotic resistance mechanisms, which are now common across the globe. The company was founded in 2010 and is headquartered in La Jolla, CA.

Aratana Therapeutics, Inc. engages in the development and commercialization of pet therapeutics. Its portfolio includes NOCITA, ENTYCE, and GALLIPRANT. NOCITA (bupivacaine liposome injectable suspension) acts as a local post-operative analgesia for cranial cruciate ligament surgery in dogs, and as a peripheral nerve block to provide regional post-operative analgesia following onychectomy in cats. ENTYCE(capromorelin oral solution) is intended for appetite stimulation in dogs. GALLIPRANT (grapiprant tablets) is for the control of pain and inflammation associated with osteoarthritis in dogs. The company was founded by Linda Rhodes and Steven St. Peter on December 1, 2010 and is headquartered in Leawood, KS.

AristaMD, Inc. develops specialty care platform and seamlessly integrate into clinical workflows. It provides eConsult solutions to empower primary care providers with clinical workup checklists and the ability to conduct electronic consults. The company was founded by Rebecca Cofinas in 2014 and is headquartered in La Jolla, CA.

Xenopharm, Inc. develops drug sensing molecules. The company was founded by Ronald M. Evans and is headquartered in Sam Mateo, CA.

Akesis Pharmaceuticals, Inc. develops and commercializes advanced therapeutics for metabolic disorder diseases such as diabetes, obesity and dyslipidemia. Akesis Pharmaceuticals was founded in 1990 and is headquartered in La Jolla, CA.

454 Life Sciences Corp. engages in the provision of medical testing services to determine the nucleotide sequence of whole genomes. The company was founded by Jonathan M. Rothberg in 2000 and is headquartered in Branford, CT.

Avalon Ventures Management LLC (Avalon Ventures Management) is a venture capital firm founded in 1983 by Kevin J. Kinsella. The firm is headquartered in La Jolla, California.

Part of Bausch Health Cos., Inc., Sytera, Inc. is a biopharmaceutical company that provides biopharmaceutical services and products. The private company is based in La Jolla, CA. The company was founded by Jay B. Lichter, Kenneth J. Widder, Nathan L. Mata. Sytera was acquired by Sirion Therapeutics, Inc. on August 16, 2006 for $250 million.

San Diego Venture Group operates as a non-profit organization that engages in the funding of start up companies. it focuses on the provision of support to the venture capital eco-system. It serves entrepreneurs, venture capitalists, community leaders, and business advisors. The company was founded in 1986 and is headquartered in San Diego, CA.

Otonomy, Inc. operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm’s product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan on May 6, 2008 and is headquartered in San Diego, CA.

Carolus Therapeutics, Inc. develops novel products for the treatment of inflammatory diseases. It company focuses on therapeutic strategies to noninvasively monitor and disrupt proinflammatory interactions of chemokines, and prevent or reverse inflammation associated with an array of human diseases, including atherosclerosis, rheumatoid arthritis, multiple sclerosis, sepsis, organ transplantation, and cancer. The company was founded by Jay Lichter, Jürgen Bernhagen, and Christian Weber in 2007 and is headquartered in San Diego, CA.

Sova Pharmaceuticals, Inc. engages in the discovery and development of human therapeutic drugs. It provides internal clinical plan on therapies supported by the mechanism, our preclinical findings, and the development of compounds reported to act on the molecular targets of H2S that include postherpetic neuralgia, chemotherapy induced peripheral neuropathic pain (CIPN pain) and diabetic neuropathy. The company’s pre-clinical findings support large-market indications, such as osteoarthritis, rheumatoid arthritis, neuropathic pain and migraine, that we would seek to develop with a strategic partner. The company was founded by Gary W. Pace and Solomon Snyder in 2010 and is headquartered in La Jolla, CA.

Avelas Biosciences, Inc. develops integrated suite of therapeutic and imaging agents for treatment of cancer. It develops AVB-620, an intravenously administered in vivo fluorescent protease activatable peptide that detects, marks, and diagnoses cancer. The company was founded by Yon Chien Tsien, Quyen T. Nguyen and Michael A. Whitney in 2008 and is headquartered in La Jolla, CA.

Sitari Pharma, Inc. provides pharmaceutical research and development services. It engages in multiple disease indications such as celiac disease. The company was founded by Chaitan S. Khosla and Thomas DiRaimondo in 2013 and is headquartered in La Jolla, CA.

COI Pharmaceuticals, Inc. provides life science investors. It offers research and development infrastructure and industry mentors to the portfolio companies of Avalon Ventures. The company was founded in 2013 and is headquartered in La Jolla, CA.

Pacific Ridge School operates a school. The non-profit company is based in Carlsbad, CA.

Synthorx, Inc. focuses on prolonging and improving lives of cancer and autoimmune disorder patients. Its product pipeline is comprised of THOR-707, IL-2 Synthorin, IL-10 Synthorin, and IL-15 Synthorin. The company was founded by Floyd E. Romesberg and Court R. Turner in 2014 and is headquartered in La Jolla, CA.

Fortis Therapeutics, Inc. operates as a immuno-oncology biotech company. It focuses on developing new antibody drug conjugate therapies for late-stage multiple myeloma and late-stage prostate cancer. The company is headquartered in La Jolla, CA.

Cellular Approaches, Inc. operates in the biotechnology industry. It develops pipeline of innate immunity cell-based therapeutics for the treatment of infectious disease, autoimmunity, neurodegeneration and aging. The company was founded in 2016 and is headquartered in La Jolla, CA.

Nerio Therapeutics, Inc. provides biotechnology services. The company is headquartered in La Jolla, CA.

Part of Cullinan Therapeutics, Inc., Cullinan Mica Corp. is a private company that provides worldwide rights to CLN-619. The company is based in Cambridge, MA. The CEO of the company is Nadim Ahmed.

Enlaza Therapeutics, Inc. is a company that develops novel classes of protein therapeutics using their proprietary war-lock™ platform. The company is based in La Jolla, CA. The company's platform utilizes synthetic biology technology for site-specific covalent coupling driven by drug binding. Enlaza Therapeutics is pioneering the field of covalent biologics and is building a pipeline of first-in-class covalent biologics. The CEO of the company is Sergio G. Duron.

John Wayne Cancer Institute is a medical institution that specializes in personalized cancer treatment. The private company is based in Santa Monica, CA. The company focuses on translating advanced cancer research into effective treatments for patients.

Silarus Therapeutics, Inc. develops therapeutics targeting erythroferrone for the treatment of iron deficiency and iron overload disorders. The company was founded by Tomas Ganz, Sanford J. Madigan, and Elizabeta Nemeth in May 19, 2014 and is headquartered in La Jolla, CA.

Thyritope Biosciences, Inc. develops therapeutics for Graves’ Orbitopathy, an auto-immune disorder caused by antibodies that over-stimulate the thyroid, causing excessive thyroid hormone production. The firm also develops therapeutics targeting erythroferrone for the treatment of iron deficiency and iron overload disorders. The company was founded by David Campbell on September 5, 2014 and is headquartered in San Diego, CA.